Experienced in WT1-Related Wilms Tumor Syndromes

Dr. Carol K. Tweed

Oncology | Hematology Oncology
Nevada Market- The US Oncology Network- McKesson Specialty Health
Maryland Oncology Hematology PA
7704 Matapeake Business Dr, Suite 200, 
Brandywine, MD 
Accepting New Patients
Offers Telehealth

Experienced in WT1-Related Wilms Tumor Syndromes
Nevada Market- The US Oncology Network- McKesson Specialty Health
Maryland Oncology Hematology PA
7704 Matapeake Business Dr, Suite 200, 
Brandywine, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Carol Tweed is an Oncologist and a Hematologist Oncology provider in Brandywine, Maryland. Dr. Tweed is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Paget Disease of the Breast, and Li-Fraumeni Syndrome. Dr. Tweed is currently accepting new patients.

Her clinical research consists of co-authoring 6 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology Oncology
Licenses
Internal Medicine in PA
Hospital Affiliations
University Of MD Shore Medical Center At Easton
University Of MD Shore Medical Ctr At Chestertown
Luminis Health Anne Arundel Medical Center, Inc
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

MARYLAND ONCOLOGY HEMATOLOGY PA
7704 Matapeake Business Dr, Suite 200, Brandywine, MD 20613
Call: 301-812-3900
Other Locations
MARYLAND ONCOLOGY HEMATOLOGY PA
7350 Van Dusen Rd, Suite 370, Laurel, MD 20707
Call: 301-982-9800
MARYLAND ONCOLOGY HEMATOLOGY PA
46 B Thomas Johnson Dr, Suite 200, Frederick, MD 21702
Call: 301-695-6777
MARYLAND ONCOLOGY HEMATOLOGY PA
10710 Charter Dr, Suite G020, Columbia, MD 21044
Call: 410-964-2218
MARYLAND ONCOLOGY HEMATOLOGY PA
11886 Healing Way, Silver Spring, MD 20904
Call: 301-933-3216

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


7 Clinical Trials

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 11, 2025
Intervention Type: Drug
Study Drugs: Palbociclib, Trastuzumab, Pertuzumab, Letrozole, Anastrozole, Exemestane, Fulvestrant
Study Phase: Phase 3
postMONARCH: A Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib Plus Fulvestrant to Placebo Plus Fulvestrant in Participants With HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy
postMONARCH: A Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib Plus Fulvestrant to Placebo Plus Fulvestrant in Participants With HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy
Enrollment Status: Active_not_recruiting
Publish Date: April 18, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Fulvestrant
Study Phase: Phase 3
A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) Alone and In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) Alone and In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Enrollment Status: Active_not_recruiting
Publish Date: January 29, 2025
Intervention Type: Drug
Study Drugs: VS-6766, Defactinib
Study Phase: Phase 2
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2)
A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2)
Enrollment Status: Completed
Publish Date: August 01, 2024
Intervention Type: Drug
Study Drugs: Trilaciclib, Gemcitabine, Carboplatin
Study Phase: Phase 3
View 6 Less Clinical Trials

5 Total Publications

Simultaneous expression of epithelial and immune cell markers in circulating tumor cells identified in patients with stage 4 breast cancer.
Simultaneous expression of epithelial and immune cell markers in circulating tumor cells identified in patients with stage 4 breast cancer.
Journal: Communications medicine
Published: October 29, 2024
View All 5 Publications
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Jeanny B. Aragon-Ching
Oncology | Hematology | Hematology Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Jeanny B. Aragon-Ching
Oncology | Hematology | Hematology Oncology

Inova Health Care Services

3300 Gallows Rd, 
Falls Church, VA 
 (22.9 miles away)
Languages Spoken:
English, Filipino
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeanny Aragon-Ching is an Oncologist and a Hematologist in Falls Church, Virginia. Dr. Aragon-Ching is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Prostate Cancer, Urothelial Cancer, Bladder Cancer, Orchiectomy, and Prostatectomy. Dr. Aragon-Ching is currently accepting new patients.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Nancy A. Dawson
Oncology | Hematology Oncology | Hematology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Nancy A. Dawson
Oncology | Hematology Oncology | Hematology

Medstar Medical Group Ii LLC

3800 Reservoir Rd Nw, 
Washington, DC 
 (19.5 miles away)
202-444-2000
Experience:
46+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Nancy Dawson is an Oncologist and a Hematologist Oncology provider in Washington, Washington, D.c.. Dr. Dawson has been practicing medicine for over 46 years and is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Prostate Cancer, Familial Prostate Cancer, WT1-Related Wilms Tumor Syndromes, and Chromophobe Renal Cell Carcinoma. Dr. Dawson is currently accepting new patients.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Noah M. Hahn
Hematology Oncology | Oncology | Hematology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Noah M. Hahn
Hematology Oncology | Oncology | Hematology

Johns Hopkins University

600 N Wolf St, 
Baltimore, MD 
 (45.4 miles away)
410-955-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Noah Hahn is a Hematologist Oncology specialist and an Oncologist in Baltimore, Maryland. Dr. Hahn is rated as an Elite provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Urothelial Cancer, Bladder Cancer, Muscle Invasive Bladder Cancer, Upper Tract Urothelial Carcinoma (UTUC), and Nephrectomy. Dr. Hahn is currently accepting new patients.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tweed's expertise for a condition
ConditionClose
    • Distinguished
    • Angiosarcoma
      Dr. Tweed is
      Distinguished
      . Learn about Angiosarcoma.
      See more Angiosarcoma experts
    • Breast Cancer
      Dr. Tweed is
      Distinguished
      . Learn about Breast Cancer.
      See more Breast Cancer experts
    • HER2 Negative Breast Cancer
      Dr. Tweed is
      Distinguished
      . Learn about HER2 Negative Breast Cancer.
      See more HER2 Negative Breast Cancer experts
    • Inflammatory Breast Cancer
      Dr. Tweed is
      Distinguished
      . Learn about Inflammatory Breast Cancer.
      See more Inflammatory Breast Cancer experts
    • Li-Fraumeni Syndrome
      Dr. Tweed is
      Distinguished
      . Learn about Li-Fraumeni Syndrome.
      See more Li-Fraumeni Syndrome experts
    • Paget Disease of the Breast
      Dr. Tweed is
      Distinguished
      . Learn about Paget Disease of the Breast.
      See more Paget Disease of the Breast experts
    • Advanced
    • ALK-Positive Non-Small Cell Lung Cancer
      Dr. Tweed is
      Advanced
      . Learn about ALK-Positive Non-Small Cell Lung Cancer.
      See more ALK-Positive Non-Small Cell Lung Cancer experts
    • Ampullary Cancer
      Dr. Tweed is
      Advanced
      . Learn about Ampullary Cancer.
      See more Ampullary Cancer experts
    • Anemia
      Dr. Tweed is
      Advanced
      . Learn about Anemia.
      See more Anemia experts
    • BRCA Positive Breast Cancer
      Dr. Tweed is
      Advanced
      . Learn about BRCA Positive Breast Cancer.
      See more BRCA Positive Breast Cancer experts
    • Childhood Iron Deficiency Anemia
      Dr. Tweed is
      Advanced
      . Learn about Childhood Iron Deficiency Anemia.
      See more Childhood Iron Deficiency Anemia experts
    • EGFR Positive Lung Cancer
      Dr. Tweed is
      Advanced
      . Learn about EGFR Positive Lung Cancer.
      See more EGFR Positive Lung Cancer experts
    View All 26 Advanced Conditions
    • Experienced
    • Acute Monoblastic Leukemia (AmoL)
      Dr. Tweed is
      Experienced
      . Learn about Acute Monoblastic Leukemia (AmoL).
      See more Acute Monoblastic Leukemia (AmoL) experts
    • Acute Mountain Sickness
      Dr. Tweed is
      Experienced
      . Learn about Acute Mountain Sickness.
      See more Acute Mountain Sickness experts
    • Adrenal Cancer
      Dr. Tweed is
      Experienced
      . Learn about Adrenal Cancer.
      See more Adrenal Cancer experts
    • Adult Soft Tissue Sarcoma
      Dr. Tweed is
      Experienced
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • Agranulocytosis
      Dr. Tweed is
      Experienced
      . Learn about Agranulocytosis.
      See more Agranulocytosis experts
    • Alveolar Soft Part Sarcoma
      Dr. Tweed is
      Experienced
      . Learn about Alveolar Soft Part Sarcoma.
      See more Alveolar Soft Part Sarcoma experts
    View All 108 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2025 All Rights Reserved